Potential new anti-malarial drug identified

February 6, 2014 by Roddy Isles, University of Dundee

A significant milestone in the development of a potential new antimalarial medicine has been reached by scientists at the University of Dundee, in partnership with the Medicines for Malaria Venture (MMV).

A compound developed in the Drug Discovery Unit at Dundee has been selected by MMV, following a positive recommendation by MMV's Expert Scientific Advisory Committee, to enter preclinical development.

Professor Ian Gilbert, Chair of Medicinal Chemistry at Dundee and one of the project leaders, said, 'This compound has impressive antimalarial properties. It has potential for a single dose treatment of malaria. It also has the possibility to protect people from getting malaria in the first place and in stopping malaria being spread from infected people to others (a feature known as transmission-blocking).'

Dr Kevin Read, co-project leader and also based at Dundee, said, 'We are very excited by this compound which belongs to a different chemical class to current . This compound will now undergo scale-up and further safety testing with a view to it entering human clinical trials within the next 18 months.'

Every year, there are over 200 million cases of malaria across the globe, resulting in about 627,000 deaths from this disease. Most of the deaths occur in children under the age of 5 and pregnant women are particularly vulnerable. There is an urgent need for new, well-tolerated, effective and affordable drugs. One reason for this is that the parasite that causes malaria is developing resistance to current medicines.

The DDU team has been working with Medicines for Malaria Venture (MMV) to identify potential new treatments for malaria.

This project began when one of the DDU collections of was screened against the parasite that causes malaria. This process identified a start point for a programme. This start point was then modified through subsequent cycles of design, synthesis and testing by expert teams of chemists and biologists, resulting in the discovery of this new antimalarial compound.

'Identifying a compound like this is no small feat,' said Dr Paul Willis, one of MMV's Drug Discovery Project Directors. 'It's a great achievement, particularly given the exciting properties of the compound, which give it potential for use in the treatment, prevention and transmission-blocking of .'

Explore further: MMV develops framework to assess risk of resistance for antimalarial compounds

Related Stories

MMV develops framework to assess risk of resistance for antimalarial compounds

August 22, 2012
Medicines for Malaria Venture has developed a framework to evaluate the risk of resistance for the antimalarial compounds in its portfolio. A paper based on this work: A framework for assessing the risk of resistance for ...

Delivery of child-friendly antimalarial hits the 100 million mark

February 22, 2012
One hundred million treatments of Coartem Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic ...

African research identifies strong candidate for possible single-dose malaria cure

August 28, 2012
A recently discovered compound from the aminopyridine class not only has the potential to become part of a single-dose cure for all strains of malaria, but might also be able to block transmission of the parasite from person ...

Open access initiative reveals drug hits for deadly neglected tropical diseases

November 13, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through ...

UT Southwestern research team's anti-malarial work wins international Project of the Year award

June 7, 2011
The discovery of a potential new anti-malarial drug by a UT Southwestern Medical Center-led research team has been awarded Project of the Year by Medicines for Malaria Venture (MMV).

Recommended for you

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

New study validates clotting risk factors in chronic kidney disease

January 17, 2018
In late 2017, researchers from Boston University School of Medicine (BUSM) discovered and published (Science Translational Medicine, (9) 417, Nov 2017) a potential treatment target to prevent chronic kidney disease (CKD) ...

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.